Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

807 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Topoisomerase I expression correlates to response to neoadjuvant irinotecan-based chemoradiation in rectal cancer.
Horisberger K, Erben P, Muessle B, Woernle C, Stroebel P, Kaehler G, Wenz F, Hochhaus A, Post S, Willeke F, Hofheinz RD; MARGIT (Mannheimer Arbeitsgruppe für Gastrointestinale Tumoren). Horisberger K, et al. Among authors: post s. Anticancer Drugs. 2009 Jul;20(6):519-24. doi: 10.1097/CAD.0b013e32832b53ff. Anticancer Drugs. 2009. PMID: 19436196 Clinical Trial.
Phase I trial of cetuximab in combination with capecitabine, weekly irinotecan, and radiotherapy as neoadjuvant therapy for rectal cancer.
Hofheinz RD, Horisberger K, Woernle C, Wenz F, Kraus-Tiefenbacher U, Kähler G, Dinter D, Grobholz R, Heeger S, Post S, Hochhaus A, Willeke F. Hofheinz RD, et al. Among authors: post s. Int J Radiat Oncol Biol Phys. 2006 Dec 1;66(5):1384-90. doi: 10.1016/j.ijrobp.2006.07.005. Epub 2006 Sep 18. Int J Radiat Oncol Biol Phys. 2006. PMID: 16979839 Clinical Trial.
mRNA expression of platelet-derived growth factor receptor-beta and C-KIT: correlation with pathologic response to cetuximab-based chemoradiotherapy in patients with rectal cancer.
Erben P, Horisberger K, Muessle B, Müller MC, Treschl A, Ernst T, Kähler G, Ströbel P, Wenz F, Kienle P, Post S, Hochhaus A, Willeke F, Hofheinz RD. Erben P, et al. Among authors: post s. Int J Radiat Oncol Biol Phys. 2008 Dec 1;72(5):1544-50. doi: 10.1016/j.ijrobp.2008.08.013. Int J Radiat Oncol Biol Phys. 2008. PMID: 19028276
Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: results of a Phase II MARGIT trial.
Horisberger K, Treschl A, Mai S, Barreto-Miranda M, Kienle P, Ströbel P, Erben P, Woernle C, Dinter D, Kähler G, Hochhaus A, Post S, Willeke F, Wenz F, Hofheinz RD; MARGIT (Mannheimer Arbeitsgruppe für Gastrointestinale Tumoren). Horisberger K, et al. Among authors: post s. Int J Radiat Oncol Biol Phys. 2009 Aug 1;74(5):1487-93. doi: 10.1016/j.ijrobp.2008.10.014. Epub 2009 Jan 7. Int J Radiat Oncol Biol Phys. 2009. PMID: 19131187 Clinical Trial.
KRAS and BRAF mutations and PTEN expression do not predict efficacy of cetuximab-based chemoradiotherapy in locally advanced rectal cancer.
Erben P, Ströbel P, Horisberger K, Popa J, Bohn B, Hanfstein B, Kähler G, Kienle P, Post S, Wenz F, Hochhaus A, Hofheinz RD. Erben P, et al. Among authors: post s. Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):1032-8. doi: 10.1016/j.ijrobp.2010.06.043. Epub 2010 Oct 13. Int J Radiat Oncol Biol Phys. 2011. PMID: 20947270 Clinical Trial.
A phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (CapIri-RT) as neoadjuvant treatment of locally advanced rectal cancer.
Willeke F, Horisberger K, Kraus-Tiefenbacher U, Wenz F, Leitner A, Hochhaus A, Grobholz R, Willer A, Kähler G, Post S, Hofheinz RD. Willeke F, et al. Among authors: post s. Br J Cancer. 2007 Mar 26;96(6):912-7. doi: 10.1038/sj.bjc.6603645. Epub 2007 Feb 27. Br J Cancer. 2007. PMID: 17325705 Free PMC article. Clinical Trial.
807 results